Ryan Specialty (NYSE:RYAN) Given New $41.00 Price Target at Barclays

Key Points

• Barclays cut its price target on Ryan Specialty to $41 (from $45) while maintaining an "overweight" rating, implying roughly a 20% upside from the prior close.
• Analyst views are mixed: MarketBeat shows a consensus rating of "Hold" with an average price target of $52.81, based on 1 Strong Buy, 9 Buy, 5 Hold and 3 Sell ratings.
• Ryan Specialty's latest quarter missed expectations — EPS $0.45 vs. $0.50 est. and revenue $751.2M vs. $777.4M est., though revenue was up 13.2% YoY — and Director Patrick G. Ryan Jr. recently bought 25,500 shares, with insiders owning 52.03% of the company.

Ryan Specialty (NYSE:RYAN - Get Free Report) had its target price lowered by investment analysts at Barclays from $45.00 to $41.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's price target suggests a potential upside of 20.17% from the company's previous close.

RYAN has been the subject of several other reports. Wells Fargo & Company dropped their target price on shares of Ryan Specialty from $63.00 to $56.00 and set an "overweight" rating for the company in a research report on Friday, February 13th. Keefe, Bruyette & Woods dropped their target price on shares of Ryan Specialty from $55.00 to $49.00 and set an "outperform" rating for the company in a research report on Tuesday. Morgan Stanley dropped their target price on shares of Ryan Specialty from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday. UBS Group dropped their target price on shares of Ryan Specialty from $71.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, February 17th. Finally, Weiss Ratings cut shares of Ryan Specialty from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $52.81.

Ryan Specialty Trading Up 1.4%

RYAN traded up $0.48 during trading on Wednesday, hitting $34.12. 395,410 shares of the stock traded hands, compared to its average volume of 2,063,726. The firm has a market capitalization of $9.01 billion, a P/E ratio of 81.04, a price-to-earnings-growth ratio of 0.88 and a beta of 0.71. The company has a debt-to-equity ratio of 2.62, a current ratio of 0.98 and a quick ratio of 0.98. The firm has a 50-day moving average of $38.98 and a 200 day moving average of $48.73. Ryan Specialty has a 12-month low of $31.50 and a 12-month high of $75.26.

Ryan Specialty (NYSE:RYAN - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). Ryan Specialty had a return on equity of 46.41% and a net margin of 7.02%.The company had revenue of $751.21 million during the quarter, compared to analysts' expectations of $777.43 million. During the same period in the prior year, the business posted $0.45 earnings per share. The company's revenue for the quarter was up 13.2% on a year-over-year basis. Equities research analysts anticipate that Ryan Specialty will post 2.29 EPS for the current year.

Insider Transactions at Ryan Specialty

In other news, Director Patrick G. Ryan, Jr. bought 25,500 shares of the firm's stock in a transaction on Monday, February 23rd. The stock was acquired at an average cost of $39.96 per share, with a total value of $1,018,980.00. Following the completion of the acquisition, the director owned 428,295 shares of the company's stock, valued at approximately $17,114,668.20. This represents a 6.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 52.03% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Fund Advisors of America Inc FL purchased a new position in Ryan Specialty in the fourth quarter worth about $277,000. Corient Private Wealth LLC raised its holdings in Ryan Specialty by 5.0% in the fourth quarter. Corient Private Wealth LLC now owns 17,807 shares of the company's stock worth $919,000 after buying an additional 840 shares during the last quarter. EJMK Ventures LLC purchased a new position in Ryan Specialty in the fourth quarter worth about $1,137,000. Caitong International Asset Management Co. Ltd raised its holdings in Ryan Specialty by 491.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,532 shares of the company's stock worth $79,000 after buying an additional 1,273 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Ryan Specialty by 21.3% in the fourth quarter. Pacer Advisors Inc. now owns 17,988 shares of the company's stock worth $929,000 after buying an additional 3,155 shares during the last quarter. 84.82% of the stock is owned by hedge funds and other institutional investors.

Ryan Specialty Company Profile

Ryan Specialty Group, Inc NYSE: RYAN is a global specialty insurance and reinsurance platform that partners with a network of insurers and reinsurers to deliver tailored risk solutions. The company focuses on complex and large-scale risks across multiple industry sectors, leveraging its underwriting expertise to structure coverage programs that meet clients' unique needs.

Ryan Specialty's core offerings span a diverse range of specialty lines, including casualty, property, professional liability, marine and energy, program administration, and sports and entertainment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.